×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Neurocrine Biosciences CFO sells over $4.1 million in company stock
Investing.com
Neurocrine (NASDAQ:NBIX) Biosciences Inc. (NASDAQ:NBIX) has reported recent stock transactions by Chief Financial Officer Matt Abernethy,...
20 hours ago
Neurocrine Wins FDA Approval for ‘Sprinkle’ Formulation of Ingrezza for Huntington’s Disease Chorea
BioSpace
Neurocrine Biosciences on Tuesday won the FDA's approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route...
2 weeks ago
Neurocrine joins in on Tardive Dyskinesia Awareness Week
Fierce Pharma
Neurocrine, maker of the first drug approved by the FDA to treat TD, is throwing its weight behind efforts to improve awareness of the...
1 week ago
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified ...
PR Newswire
CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults...
3 days ago
US FDA approves Neurocrine Biosciences' movement disorder drug
Reuters
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement...
2 weeks ago
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Yahoo Finance
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc.
2 weeks ago
Morgan Stanley Reiterates Neurocrine Biosciences (NBIX) Overweight Recommendation
MSN
Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight recommendation.
2 days ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $1,695,375.00 in Stock
MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Gary A. Lyons sold 12500 shares of the company's stock in a...
17 hours ago
Neurocrine Biosciences (NBIX) Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for ...
StreetInsider
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented baseline data from the CAHtalyst™...
3 days ago
Neurocrine Biosciences Is Making Good On Its Ingrezza Diversification, And Its Biotech Stock Is Flying
Investor's Business Daily
Neurocrine Biosciences (NBIX) is making good on its promise to diversify from its blockbuster drug Ingrezza. And, with a bevy of good news...
1 week ago